Small Pharma Inc. (DMT.V)
| Previous Close | 0.1650 |
| Open | 0.1800 |
| Bid | 0.1650 x N/A |
| Ask | 0.1700 x N/A |
| Day's Range | 0.1650 - 0.1800 |
| 52 Week Range | 0.1600 - 0.7000 |
| Volume | |
| Avg. Volume | 134,254 |
| Market Cap | 54.026M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1760 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.38 |
- GlobeNewswire
Small Pharma to Participate in the PSYCH Symposium: London 2022
Conference to take place at The National Gallery in London on May 11, 2022LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, will participate in the PSYCH Symposium: London 2022 – Shaping The Future Of Psychedelic Healthcare. Dr. Carol Routledge, Small Pharma’s Chief Medical and Scientific Officer, will join a panel dis
- GlobeNewswire
KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing
NEW YORK, April 29, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27th and 28th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing. REGISTER OR LOGIN NOW AT: https://bit.ly/3OGHgD4 The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Comp
- GlobeNewswire
Small Pharma To Present At The KCSA Psychedelics Virtual Investor Conference On April 28, 2022
Live Presentation To Take Place at 9:30AM ET / 2:30PM GMTLONDON, April 27, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that Peter Rands, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, will present live at the KCSA Psychedelics Virtual Investor Conference at www.virtualinvestorco
